Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 113 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer March 15, 2022 NCI-MATCH Update: More Labs, New Arms, and Initial Findings November 15, 2018 PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows May 11, 2020 Study Reinforces Treatment Idea for Cancer with Microsatellite Instability October 2, 2020 Load more HOT NEWS Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells Foodie Fridays-Gazpacho: A Favorite Summer Soup Rapid Genetic Test Could Help Guide Brain Cancer Surgery Prostate cancer: Lessons Learned from My Breast Cancer
